On Thursday shares of International Business Machines Corporation (NYSE:IBM) closed at $170.24. Company’s sales growth for last 5 years was -0.60% and EPS growth for next 5 years is recorded as 5.15%. International Business Machines Corporation (NYSE:IBM) announced that SoftLayer, an IBM Company, has opened a second cloud data center in the Netherlands, located in Almere, just outside of Amsterdam. The new facility will doublw IBM’s SoftLayer capacity in the region, and provides even more options in the country and region for redundant data storage and geographically isolated services, ideal for creating secure and comprehensive backup and recovery strategies.
China Ceramics Co., Ltd. (NASDAQ:CCCL) in last trading activity advanced 4.34% to close at $1.33. Company weekly performance is -4.32% while its quarterly performance stands at 47.78%. China Ceramics Co., Ltd. (NASDAQ:CCCL) is -31.44% away from its 52 week high. On April 14, China Ceramics Co., Ltd. (Nasdaq:CCCL) reported Q4 EPS of RMB0.23, versus (RMB0.52) reported last year. Revenue for the quarter came in at RMB240.1 million, versus RMB220.3 million reported last year.
On last trading day Jack Henry & Associates Inc. (NASDAQ:JKHY) advanced 0.16% to close at $68.14. Its volatility for the week is 1.10% while volatility for the month is 1.33%. JKHY’s sales growth for past 5 years was 10.20% and its EPS growth for past 5 years was 14.10%. Jack Henry & Associates Inc. (NASDAQ:JKHY) monthly performance is -1.79%. Jack Henry & Associates, Inc. (NASDAQ:JKHY) announced that it will host a live Webcast of its third quarter 2015 earnings conference call on May 7, 2015. The press release announcing third quarter earnings will be issued after market-close on May 6, 2015.
ArQule Inc. (NASDAQ:ARQL) has 1.10% insider ownership while its institutional ownership stands at 49.20%. In last trading activity company’s stock closed at $2.12. On April 21, ArQule, Inc. (Nasdaq:ARQL) announced that data with ARQ 087, a potent FGFR (Fibroblast Growth Factor Receptor) inhibitor, will be presented at the 2015 Annual Meeting of the American Association for Cancer Research (AACR). ARQ 087 is currently in a Phase 2 trial in patients with Intrahepatic Cholangiocarcinoma (iCCA) with FGFR2 fusions and a Phase 1b trial in adrenocortical tumors and tumors with FGFR translocations, amplification and mutations.
On last trading day Belden Inc. (NYSE:BDC) advanced 1.44% to close at $95.14. Its volatility for the week is 1.79% while volatility for the month is 2.04%. BDC’s sales growth for past 5 years was 11.10% and its EPS growth for past 5 years was 65.90%. Belden Inc. (NYSE:BDC) monthly performance is 3.54%. Belden Inc (NYSE:BDC)‘s stock had its “buy” rating reaffirmed by equities research analysts at Canaccord Genuity in a research note issued to investors on Sunday. They currently have a $112.00 price objective on the stock.